PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events-Reference-Cited by-同舟云学术

PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events

Published:2008 Issue:2 Volume:7 Page:121-129
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Hughes Sara,Hughes Arlene,Brothers Cindy,Spreen William,Thorborn Daren,

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Reference13 articles.

1. Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

2. , et al. Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8000 subjects receiving abacavir in 34 clinical trials. Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract H-2013, Chicago IL, USA, 14–17 September 2003.

3. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

4. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction

5. Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review;Therapeutic Drug Monitoring;2024-09-11

2. Chimeric cohorts and consortia can power and scale precision medicine;Comprehensive Precision Medicine;2024

3. HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV;Pharmacogenomics;2023-09-28

4. HIV-positive women have higher prevalence of comorbidities and anticholinergic burden: assessment of the HIV-positive population from Menorca (Balearic Islands);AIDS Care;2022-04-27

5. The Immunogenetics of Cutaneous Drug Reactions;The Immunogenetics of Dermatologic Diseases;2022